Truist Financial Corp Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Truist Financial Corp lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 4,007 shares of the biopharmaceutical company’s stock after buying an additional 383 shares during the quarter. Truist Financial Corp’s holdings in Alnylam Pharmaceuticals were worth $1,307,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ALNY. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after purchasing an additional 323,206 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Alnylam Pharmaceuticals in the 1st quarter worth about $69,292,000. Adage Capital Partners GP L.L.C. raised its position in Alnylam Pharmaceuticals by 203.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company’s stock worth $76,195,000 after buying an additional 189,128 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock worth $946,466,000 after buying an additional 185,783 shares during the last quarter. Finally, SCS Capital Management LLC purchased a new position in Alnylam Pharmaceuticals in the 1st quarter worth about $46,194,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.6%

Alnylam Pharmaceuticals stock opened at $459.66 on Monday. The business has a 50-day simple moving average of $451.37 and a two-hundred day simple moving average of $346.13. The company has a market cap of $60.25 billion, a P/E ratio of -186.10 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the transaction, the executive vice president owned 54,052 shares in the company, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Tolga Tanguler sold 1,405 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $635,130.25. Following the transaction, the executive vice president owned 27,438 shares in the company, valued at approximately $12,403,347.90. This trade represents a 4.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Royal Bank Of Canada boosted their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research report on Friday, September 19th. Piper Sandler boosted their target price on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. UBS Group boosted their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Morgan Stanley boosted their target price on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research report on Monday, October 6th. Finally, Citigroup boosted their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Twenty-four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $457.16.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.